Niels Riedemann

Niels Riedemann

Company: InflaRx Group

Job title: Chief Executive Officer & Founder


Targeting Complement Driven Neutrophil Activation in HS: Lessons Learned & Strategies Going Forward for Vilobelimab, a New First-in-class Anti-C5a Antibody 1:30 pm

• Examining new research suggesting that a key role of neutrophils in HS draining tunnel development and disease progression • Exploring vilobelimab that targets this mechanism and has demonstrated efficacy on reduction of all 3 inflammatory lesions but especially on draining tunnels • Evaluating lessons learned from a failure to demonstrate efficacy on the currently…Read more

day: Day 2 PM - Track 2

© Copyright 2022 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.